Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer

NCT03396926 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT03396926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03396926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
April 18, 2018
Completion date
January 30, 2024
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microsatellite stable, mismatch repair protein proficient, stage iii colorectal cancer ajcc v7, stage iiib colorectal cancer ajcc v7, stage iiic colorectal cancer ajcc v7, stage iv colorectal cancer ajcc v7, stage iva colorectal cancer ajcc v7, stage ivb colorectal cancer ajcc v7